Last reviewed · How we verify
Microcyn
Microcyn, developed by the University of Alabama at Birmingham, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Microcyn |
|---|---|
| Also known as | Microcyn® Skin and Wound Care with preservatives |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pressure Ulcer Healing With Microcyn (PHASE4)
- A Substantial Equivalence Study of RD04723 and Predicate Device (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microcyn CI brief — competitive landscape report
- Microcyn updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI